Project Grant R01CA295603
Award Date 8/18/25
Completion Date 7/30/29
Dollars Obligated $2.8M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
- This $369,868 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to investigate the role of intercellular mitochondrial transfer between nerves and cancer cells, particularly in the context of triple-negative breast cancer metastasis. The project aims to determine how this mitochondrial transfer impacts the metastatic potential of cancer cells and identify key mediators of the process, with the goal of developing potential...
- This $422,799 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Maryland, Baltimore supports research to understand and mitigate the mechanisms of treatment resistance in chimeric antigen receptor (CAR) T cell therapy for blood cancers. The research aims to characterize the process of CAR-mediated trogocytosis, in which target antigens are transferred from tumor cells to CAR T cells, leading to rapid loss of the target antigen...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,500.00 to Chapman University to develop peptide-doxorubicin conjugates that can mitigate the cardiotoxicity and overcome drug resistance associated with the chemotherapy drug doxorubicin. The 3-year project aims to investigate the mechanisms by which five peptide-doxorubicin conjugates can selectively target and kill drug-resistant cancer cells while reducing toxicity to...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is providing $518,219.00 to support research focused on deciphering the molecular mechanisms underlying the development of cholangiocarcinoma (CCA), a type of liver cancer. The research aims to investigate the intertwined roles of the nuclear receptors FXR and CAR in the transformation of hepatocytes into CCA, particularly in the context of cholestatic liver diseases that significantly...
- This federal Project Grant award, valued at $768,567.00 and awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) on September 15, 2025, supports research on the use of the PET imaging tracer 68Ga-GALMYDAR to detect cardiotoxicity induced by chemotherapeutic agents like doxorubicin. The award recipient, The Washington University, will conduct in vitro and in vivo studies to evaluate the potential of this novel imaging biomarker to provide an...
- This $683,472 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop pharmacodynamically directed targeted therapies for acute myeloid leukemia (AML). The primary awardee, the University of Cincinnati's Sponsored Research Services Division, is conducting preclinical studies on using small molecule inhibitors of the enzyme DHODH to differentiate AML cells from normal hematopoietic stem cells and activate the immune...
- This federal Project Grant award of $531,379.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of California, Los Angeles (UCLA) aims to evaluate mitochondrial networks as a critical determinant of response to antibody drug conjugates (ADCs) in advanced/metastatic non-small cell lung cancer (NSCLC). The study will leverage novel structural and functional analysis techniques integrating PET imaging and ultra-resolution microscopy to investigate...
- This federal Project Grant award of $1,271,780.00 was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Pittsburgh. The funding will support research aimed at developing small molecule adaptors for precisely controlling and enhancing the targeting capabilities of chimeric antigen receptor (CAR) T cell therapies. The key objectives are to: 1) Create small molecule adaptors for targeting universal CAR T cells to multiple antigens, including...
- This $465,020 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research focused on understanding how chemotherapy can inadvertently activate membrane-anchored serine proteases (MASPs) on ovarian cancer cells, which can then promote tumor dissemination and metastasis. The five-year grant, which commenced on February 1, 2025, will enable researchers at the University of Maryland, Baltimore to investigate the...